PharMerica (PMC) Tops Q2 EPS by 10c; Boosts FY13 Outlook
Tweet
Share
E-mailGet Alerts PMC Hot Sheet
Join SI Premium – FREE
PharMerica (NYSE: PMC) reported Q2 EPS of $0.44, $0.10 better than the analyst estimate of $0.34. Revenue for the quarter came in at $458.5 million versus the consensus estimate of $414.15 million.
PharMerica sees FY2013 EPS of $1.55-$1.60, versus prior guidance of $1.39-$1.55 and the consensus of $1.49. PharMerica sees FY2013 revenue of $1.625-$1.675 billion, versus prior guidance of $1.567-$1.694 billion and the consensus of $1.66 billion.
For earnings history and earnings-related data on PharMerica (PMC) click here.
PharMerica sees FY2013 EPS of $1.55-$1.60, versus prior guidance of $1.39-$1.55 and the consensus of $1.49. PharMerica sees FY2013 revenue of $1.625-$1.675 billion, versus prior guidance of $1.567-$1.694 billion and the consensus of $1.66 billion.
For earnings history and earnings-related data on PharMerica (PMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
- Sandisk targets mid-to-high teens revenue growth through FY2030
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
